← Back to all trials
Active Not Recruiting
NCT07274241
Escitalopram and the Risk of Serious Adverse Events
Conditions: Chronic Kidney Disease (CKD), Elderly, Outpatient
Sex: All
Ages: 66 Years – N/A
Enrollment: 12145
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Location: London Health Sciences Centre Research Institute London Ontario
Summary
The goal of this population-based cohort study is to assess the safety of initiating a new outpatient prescription of 10mg/day of Escitalopram (higher dose) compared to 5 mg/day (lower dose) in adults over the age of 65 with low kidney function.
Primary question
Whether initiating a new outpatient prescription of a higher dose of Escitalopram (10mg/day) compared to a lower dose (5 mg/day) in older adults with low kidney function (an eGFR \
Eligibility Criteria
Inclusion Criteria:
* Older adult aged 66 years or greater with low kidney function (an eGFR \
Source: ClinicalTrials.gov (NCT07274241). StuddyBuddy aggregates publicly available trial information.
